Aquestive Therapeutics (AQST) Income from Continuing Operations: 2017-2025
Historic Income from Continuing Operations for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to -$15.4 million.
- Aquestive Therapeutics' Income from Continuing Operations fell 34.21% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.0 million, marking a year-over-year decrease of 96.00%. This contributed to the annual value of -$44.1 million for FY2024, which is 460.83% down from last year.
- As of Q3 2025, Aquestive Therapeutics' Income from Continuing Operations stood at -$15.4 million, which was down 14.01% from -$13.5 million recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Income from Continuing Operations registered a high of $8.1 million during Q1 2023, and its lowest value of -$28.9 million during Q4 2021.
- In the last 3 years, Aquestive Therapeutics' Income from Continuing Operations had a median value of -$11.5 million in 2024 and averaged -$9.4 million.
- Per our database at Business Quant, Aquestive Therapeutics' Income from Continuing Operations spiked by 161.03% in 2023 and then tumbled by 465.55% in 2024.
- Aquestive Therapeutics' Income from Continuing Operations (Quarterly) stood at -$28.9 million in 2021, then soared by 57.33% to -$12.4 million in 2022, then surged by 34.33% to -$8.1 million in 2023, then tumbled by 110.27% to -$17.1 million in 2024, then slumped by 34.21% to -$15.4 million in 2025.
- Its Income from Continuing Operations stands at -$15.4 million for Q3 2025, versus -$13.5 million for Q2 2025 and -$22.9 million for Q1 2025.